- Case report
- Open Access
- Open Peer Review
Small cell neuroendocrine tumor of the breast in a 40 year-old woman: a case report
© Nicoletti et al; licensee BioMed Central Ltd. 2010
- Received: 26 January 2008
- Accepted: 30 June 2010
- Published: 30 June 2010
Small cell neuroendocrine cancer of the breast is a rare tumor with less than 30 cases reported in the literature. The morphological and immunohistochemical patterns of this tumor are similar to small cell neuroendocrine cancer of the lung. For this reason, it is often difficult to distinguish a primary small cell neuroendocrine cancer of the breast from a metastatic lesion from other sites.
We report and characterize with immunohistochemical techniques a case of primary small cell neuroendocrine cancer of the breast occurring in a 40-year-old Caucasian woman. A palpable and mobile 3.0 cm tumor was located in the upper-outer quadrant of her right breast. Lumpectomy and subsequent radical mastectomy with axillary lymph node resection were performed. Microscopically, the tumor consisted predominantly of a diffuse proliferation of small oat cells. The tumor cells were positive for neuroendocrine markers chromogranin A and synaptophysin. One of 16 lymph nodes was metastatic. A correct treatment needs to be chosen.
It has recently been demonstrated that early small cell neuroendocrine cancer of the breast shows a good prognosis with adjuvant treatments with high disease free survival. Our patient is alive and well without disease eight years after treatment. We performed an adjuvant therapy with the classic scheme doxorubicin and cyclophosphamide, followed by carboplatin and etoposide. A more extensive review is required to define a standard treatment protocol for this rare neoplasm.
- Small Cell Neuroendocrine Carcinoma
- Neuroendocrine Cancer
- Luteal Hormone
- Degree Family History
Neuroendocrine (NE) carcinomas of the breast are defined by the diffuse expression of NE markers (chromogranins and/or synaptophysin) in ≥50% of cells. This definition includes lesions with pure NE phenotype as well as variants which may co-express mucinous and/or apocrine phenotype. The existence of primary breast carcinoid tumors is still controversial and, if accepted, it would account for less than 1% of primary breast cancers . In this report, we describe a case of primary small cell neuroendocrine carcinoma (SCNC) of the breast occurring in a 40-year-old woman.
With immunohistochemical analysis, a distinction between a primary tumor and a metastatic lesion is possible: SCNC of the breast is positive for cytocheratin 7 and negative for cytocheratin 20, whereas the SCNC of the lung is negative for both. SCNC of the breast can be confused also with a lobular breast cancer. Generally, in SCNC an electron microscopy will show neurosecretory granules, which are reminiscent of the argyrophil variant of lobular carcinoma of the breast. Lobular carcinoma is always negative for Caderin E, whereas SCNC is positive in 100% of cases as in this situation.
Our patient was treated with chemotherapy, doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) with four cycles every 21 days, followed by carboplatin 300 mg/m2 during day one and etoposide 120 mg/m2 during days one to three, (CE) for three cycles every 28 days. These drugs were chosen for their described efficacy both in breast carcinoma as in SCLC. Cisplatin or carboplatin with etoposide are considered standard treatments in SCLC [2–4], while doxorubicin is the most used drug for breast carcinoma and is also active in SCLS. Hematological and clinical compliance was poor with main toxicities being neutropenia G3 and fatigue G2. No major complications were observed and our patient completed treatment at the full dosage. In consideration of the positive hormonal status and of the negative c-erb-B2, after chemotherapy, our patient received tamoxifen 20 mg daily for five years plus LH-RH analogues for two years. Our patient underwent a regular follow-up check-up every six months. After 18 months, tamoxifen was discontinued for intolerance and minor vascular complications, and was replaced with anastrozole from November 2005. At that time, our patient became amenorrhoic and follicle-stimulating hormone (FSH) and luteal hormone (LH) were compatible with menopausal status. Our patient is alive and well without disease after eight years.
Small cell (oat cell) neuroendocrine cancer of the breast is a rare tumor with fewer than 30 cases reported in the literature. The morphological and immunohistochemical patterns of this tumor are similar to SCNC of the lung . For this reason, it is often difficult to distinguish a primary SCNC of the breast from a metastatic lesion from other sites [6–8]. Literature shows very poor prognosis for the SCNC of the breast without adjuvant treatment. These tumors often arise with extensive vascular invasion, nodal involvement, high proliferation index and more frequently, without estrogen and progesterone expression [9–11]. Mucin production is a common feature in NE breast tumor and the mucinous differentiation is an important indicator of low biological aggressiveness. Estrogen and progesterone expression is also correlated with a better prognosis .
Wade et al. described in 1983 the first SCNC of the breast. Another seven cases were described in the period 1983 to 1995 with extremely poor prognoses (median survival nine to ten months). Currently, SCNC of the breast is considered an extremely aggressive tumor for which there is no general agreement about a standardized treatment [12, 13]. The best choice seems to be radical mastectomy with axillary resection followed by a chemotherapy combining anthracycline and effective drugs for small call carcinoma (platinum compounds and etoposide). We adopted this therapeutic choice for our patient, adding hormonal treatment at the light of the positive hormonal receptor status. Our patient is still alive and well without disease eight years after surgery and medical treatment.
Small cell (oat cell) neuroendocrine cancer of the breast is a rare tumor. It has been recently demonstrated that early SCNC of the breast shows a good response to adjuvant treatment with a disease free survival ranging between 33 and 48 months. Further studies with more cases are required to define more precisely treatment indications for this rare neoplasm.
Written informed consent was obtained from our patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Sapino A, Papotti M, Righi L, Cassoni P, Chiusa L, Bussolati G: Clinical significance of neuroendocrine carcinoma of the breast. Ann Oncol. 2001, 12: 115-117. 10.1023/A:1012417903068.View ArticleGoogle Scholar
- Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol. 1994, 21 (3 Suppl 6): 23-30.PubMedGoogle Scholar
- Brahmer JR, Ettinger DS: Carboplatin in the treatment of small cell lung cancer. The Oncologist. 1998, 3: 143-154.PubMedGoogle Scholar
- Okuno SH, Jett RJ: Small cell lung cancer: current therapy and promising new regimens. Oncologist. 2002, 7: 234-238. 10.1634/theoncologist.7-3-234.View ArticlePubMedGoogle Scholar
- Shin SJ, De Lellis RA, Ying L, Rosen PP: Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients. Am J Surg Pathol. 2000, 24: 1231-1238. 10.1097/00000478-200009000-00006.View ArticlePubMedGoogle Scholar
- Salaman WD, Harrison JAF, Howat AJ: Small cell neuroendocrine carcinoma of the breast. J Clin Pathol. 2006, 59: 888-891. 10.1136/jcp.2005.032607.View ArticleGoogle Scholar
- Papotti M, Gherardi G, Eusebi V, Pagani A, Bussolati G: Primary oat cell (neuroendocrine) carcinoma of the breast. Report of four cases. Arc A Pathol Anat Histopathol. 1992, 420: 103-108. 10.1007/BF01605991.View ArticleGoogle Scholar
- Sebenik M, Nair SG, Hamati HF: Primary small cell anaplastic carcinoma of the breast, diagnosis by fine needle aspiration cytology: a case report. Acta Cytol. 1998, 42: 1199-1203.View ArticlePubMedGoogle Scholar
- Yamasaki T, Shimazaki H, Aida S, Tamai S, Tamaki K, Hiraide H, Mochizuchi H, Matsubara O: Primary small cell (oat cell) carcinoma of the breast: report of a case and review of the literature. Histopathology. 2001, 38: 277-278. 10.1046/j.1365-2559.2001.01068.x.View ArticleGoogle Scholar
- Salmo EN, Connolly CE: Primary small cell carcinomas of the breast: report of a case and review of the literature. Histopathology. 2001, 38: 277-278. 10.1046/j.1365-2559.2001.01068.x.View ArticlePubMedGoogle Scholar
- Wade PM, Mills SE, Read M, Cloud W, Lambert MJ: Small cell neuroendocrine (oat cell) carcinoma of the breast. Cancer. 1983, 52: 121-125. 10.1002/1097-0142(19830701)52:1<121::AID-CNCR2820520122>3.0.CO;2-F.View ArticlePubMedGoogle Scholar
- Jochems L, Tjalma WA: Primary small cell neuroendocrine tumour of the breast. Eur J Obstet Gynecol Reprod Biol. 2004, 115: 231-233. 10.1016/j.ejogrb.2003.12.013.View ArticlePubMedGoogle Scholar
- Bigotti G, Coli A, Butti A, Del Vecchio M, Tartaglione R, Massi G: Primary small cell neuroendocrine carcinoma of the breast. J Exp Clin Cancer Res. 2004, 23: 691-696.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.